Meeting
2020 ASCO Virtual Scientific Program
Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.
Authors
Michael Rahman Shafique
Department of Thoracic Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL
Michael Rahman Shafique , Terrence Lee Fisher , Elizabeth E. Evans , John E. Leonard , Desa Rae Electa Pastore , Crystal L. Mallow , Ernest Smith , Andreas Schröder , Kevin M. Chin , Joseph Thaddeus Beck , Megan Ann Baumgart , Ramaswamy Govindan , Nashat Y. Gabrail , Rachel E. Sanborn , Alexander I. Spira , Nagashree Seetharamu , Yanyan Lou , Aaron Scott Mansfield , Jonathan Wade Goldman , Maurice Zauderer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT03268057
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3011)
DOI
10.1200/JCO.2020.38.15_suppl.3011
Abstract #
3011
Poster Bd #
75
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: A consecutive analysis of NSCLC patients with high PD-L1 expression.
First Author: Hiroshi Takumida
Poster
2020 Genitourinary Cancers Symposium
Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer PD-L1+ unfit for cisplatin: The ARIES study.
First Author: Roberto Iacovelli
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Prognostic value of PD-L1+CD4+ T cells in non-small cell lung cancer (NSCLC) patients treated with a PD-1 inhibitor.
First Author: Kiriaki E. Vetsika
Poster
2016 ASCO Annual Meeting
Meta-analysis of tumor PD-L1 expression as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors in solid tumors.
First Author: Monica Khunger